Despite Q1 profit decline, Elevance Health raises financial outlook
Summarize this article with:
Despite Q1 profit decline, Elevance Health raises financial outlook Cost control, Carelon integration and scaling AI are reasons for the company's confidence. Accounting & Financial Management By Susan Morse , Executive Editor | April 22, 2026 | 10:09 AM Photo: Jet City Image/Getty Images Despite a reported 19.4% drop in profit for the first quarter, Elevance Health's financial results exceeded expectations.For Q1, Elevance reported net income of $1.76 billion, compared with $2.18 billion in Q1 2025.President and CEO Gail Boudreaux expressed confidence in the company's financial outlook, saying that for 2027, Elevance is expected to return to 12% earnings per share growth.The company is bolstered by cost control, investments in AI and Carelon's clinical opportunities, areas Boudreaux addressed during Wednesday's earnings call.Elevance has realigned its health benefits segment and subsidiary Carelon to integrate pharmacy, specialty benefits and behavioral health. As a result, hospital readmissions have been reduced by 20%, Beaudreaux said.Predictive analytics supported by AI is identifying members at risk for health concerns, including substance use disorder. AI is embedded in clinical operational workflows and is scaled across the organization. This is allowing for earlier preventions and has reduced administrative expenses through automation, she said."We're already seeing tangible results," Boudreaux said. Elevance has strong retention in the Affordable Care Act market through Bronze tier plans.In the commercial market, the company is seeing an uptick in employer interest for 2027 due to disciplined pricing."Employers are focusing on affordability," said AJ Koett, business information consultant for Elevance Health.Headwinds include a February notice from the Centers for Medicare and Medicaid Services on potential sanctions due to Medicare Advantage risk adjustment data reporting. In March, CMS granted Elevance's request to extend the date that sanctions could be imposed – to May 30 from March 31."We're making steady progress towards resolution," Boudreaux said. "This matter does not affect our outlook and how we serve our members."FINANCIALSElevance's operating revenue of $49.5 billion for the quarter reflected a 1.5% increase from the same quarter last year.Earnings per share guidance of $19.85 for 2026 includes the company's estimate of the financial impact of the CMS matter. FY 2026 adjusted diluted EPS guidance was raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs and increased visibility.The company expects FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter.THE LARGER TRENDEarlier this month, Elevance Health announced a series of leadership appointments across its Health Benefits and Carelon organizations.The appointments, Elevance said, supported the continued expansion of Carelon that Elevance launched in 2022.ON THE RECORD"Our first-quarter results exceeded expectations, reflecting underlying business strength and improving claims experience. We are raising our full-year adjusted EPS guidance, supported by greater visibility into the balance of the year. Our actions are driving more consistent performance and position Elevance Health for continued improvement over time,” Boudreaux said by statement. Email the writer: [email protected] Topic: Accounting & Financial Management, Artificial Intelligence, Business Intelligence, Operations